Quince Therapeutics Files Audited Orphai Financials and Pro Forma Combined Information for May 2026 Acquisition
QNCX sits 26% above its 52-week low of $15.1.
Summary
Quince Therapeutics filed an amended 8-K with audited Orphai financials and pro forma combined information, revealing a combined $491.6M accumulated deficit and $157.1M net loss for 2025, while detailing the $115M private placement's impact and ongoing going concern risks.
Key Events · M&A and Partnerships · QNCX
-
Audited Orphai Financials Disclosed
Orphai's audited financials show net losses of $11.3M (2025) and $10.7M (2024), with an accumulated deficit of $127.0M as of Dec 31, 2025, and a going concern warning.
-
Pro Forma Combined Losses
Pro forma combined net loss for 2025 is $157.1M, including a $59.0M IPR&D charge and $6.4M in acquisition costs, with a combined accumulated deficit of $491.6M.
-
Private Placement Impact
The $115M private placement is reflected in the pro forma balance sheet, but proceeds are contingent on stockholder approval to convert Series C Preferred Stock; failure could force cash settlements.
-
Integration and Dilution Risks
Risk factors highlight integration challenges, the need for stockholder approval to increase authorized shares to 800M, and potential dilution from Series C Preferred Stock conversion and warrants.
Analysis · QNCX · Life Sciences
This amendment delivers the first look at Orphai's audited financials and pro forma combined results, closing a critical information gap left by the May 18 acquisition announcement. The numbers lay bare Orphai's historical losses, going concern doubts, and the $115M private placement's effect on the combined balance sheet. Pro forma statements reveal a combined accumulated deficit of $491.6M and a net loss of $157.1M for 2025, underscoring the steep cash burn and dilution risk ahead. Adding Orphai's risk factors also spotlights integration challenges and the need for stockholder approval to convert Series C Preferred Stock—failure to secure it could force cash settlements.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $18.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.